![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/4/2019 15:48 | 85.000 ADR's equal to 425.000 shares just traded on Nasdaq at 1,86 equal to 28,8p | ![]() multiplural | |
29/4/2019 09:00 | Bought a few more on the minidip | ![]() volsung | |
26/4/2019 17:28 | Come on summit pull your finger out or something elsehttps://www.dail | ![]() football | |
23/4/2019 21:02 | Better day on the Nasdaq | ![]() kirk 6 | |
23/4/2019 18:32 | That should bring a load of new investors | ![]() kirk 6 | |
23/4/2019 09:02 | Summit Therapeutics management to meet with Canaccord Meeting to be held in New York on April 24 hosted by Canaccord. Read more at: | ![]() football | |
22/4/2019 20:16 | " Superbugs linked to eight out of 10 deaths in Bangladeshi ICUs..." | ![]() algernon2 | |
22/4/2019 17:53 | That's better some more big bids coming in | ![]() kirk 6 | |
22/4/2019 16:02 | That's been on there for a few weeks. Partial fill now | ![]() kirk 6 | |
22/4/2019 14:57 | There is a bid in for 125.000 ADR's at 1,85. That is a bid equalling 625.000 shares at 28.50p . I can't remember having seen bids that size recently. | ![]() multiplural | |
22/4/2019 14:57 | Anyone know why the Nasdaq is lagging? | ![]() kirk 6 | |
22/4/2019 07:54 | Here is a story i heard on radio 4 this morning, an Antibiotic developed and approved in the states, the firm has just gone bankrupt. A director of the Welcome foundation was interviewed and he said, " Antibiotics are low revenue and low usage' so in the states you can't charge loads and use is being limited to prevent overuse'. He went on to say they are lobbying for government to change the way firms are rewarded for developing new antibiotics as the current system doesn't work. | ![]() hernando2 | |
22/4/2019 07:26 | And more 'noise' based on the above FT article (author just been on Today programme) a tweet from Scott Gottlieb (recent FDA head) yesterday. Another option: Change the payment paradigm for hospital use antibiotics completely; move from a system that pays for each prescription to one where hospitals pay an annual license fee for access to drugs for resistant pathogens. That aligns incentives, creates a natural market. | ![]() waterloo01 | |
21/4/2019 17:53 | There does seem to be more 'noise' currently, both in the UK/EU and the US about the urgent need to fund antibiotics differently. We need real change now. The amounts that need to be injected are high — about $1bn per drug. That’s a hard sell for politicians, but it reflects the value of antibiotics. The cost could be shared among countries: for the UK to contribute 5 per cent, for example, of an additional $1bn a year for antibiotic development would cost about 6p per person per month. This is a problem we can afford to solve. If leaders are afraid to deliver these types of market incentives, we need to offer a plan B — finding creative new models to stabilise the antibiotics market and stimulate private sector innovation without exposing public funders to all the risk. If we do not act, the biggest losers will not be the investors, staff and shareholders of companies such as Achaogen, but patients and the public. | ![]() waterloo01 | |
19/4/2019 15:19 | kirk6, well that's a bit of a leap but with them linked into Carb-X, BARDA, Wellcome and the likes of the Gates foundation and Duggan as the key investor, they will get there eventually but what will really set the sector alight is a change in sentiment towards antibiotics. | ![]() waterloo01 | |
19/4/2019 15:08 | That's great news again for summit shows funding will likely be available for full commercialisation | ![]() kirk 6 | |
19/4/2019 14:40 | Summit tweeted this link out as it's STD awareness month (who knew such a thing existed!) Through the National Strategy to Combat Antibiotic-Resistant Bacteria (CARB)—we arm state and local health departments with tools to stay a step ahead of resistant gonorrhea—one of the nation’s most urgent public health threats They got some funding via CARB-X and would expect more such grants to follow. | ![]() waterloo01 | |
17/4/2019 09:25 | There has been steady buying recently here and with the potential you can see why. We must be on the edge of the next major surge higher into the 40s | ![]() kirk 6 | |
16/4/2019 15:41 | Excellent read that. This could well be the share of 2019 - just need the Nasdaq to rise | ![]() kirk 6 | |
16/4/2019 15:12 | A further article: Summit Therapeutics well placed in the race to find next-generation antibiotic investors.co.uk/news | ![]() chrisatrdg | |
15/4/2019 23:06 | Summit Therapeutics soars as it hails potential of very early stage antibiotic | ![]() football | |
15/4/2019 20:12 | I have never bought here and was interested in this article in yesterday's Sunday Telegraph | ![]() cerrito |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions